Investor Education Series: China’s Biotechnology Boom
China’s biotechnology sector has emerged as a significant area of focus within Hong Kong’s equity markets. As of end-May 2026, Hong Kong is home to around 280 healthcare and biotech companies with a total market capitalisation of approximately HKD 3.9 trillion, establishing the city as a leading biotech listing hub. This educational overview examines the sector's development, key drivers, and the regulatory environment in Hong Kong.
Why the sector is gaining momentum
China’s population is ageing, with more than 20% aged 60 or above1, a proportion expected to rise further in the coming years. Demographic shifts can influence healthcare demand patterns, including potential growth in treatments for chronic disease, oncology, and other age-related conditions.
Biotechnology has been identified within China's policy framework as part of efforts to develop “new quality productive forces”, with biological manufacturing identified as a growth driver in the country’s 15th Five-Year Plan. Policy direction can affect sector ecosystems, including research capacity, talent development and commercialisation pathways.
Chinese biotechnology companies have expanded their global footprint2, while international pharmaceutical firms have increased acquisitions and licensing arrangements in China3. Such developments can influence sector dynamics and market perceptions.
Why Hong Kong matters for investors
Hong Kong's capital markets feature specific regulatory arrangements that market participants should understand. Hong Kong listing rules include provisions (Chapter 18A) that allow eligible biotechnology companies, a framework that has welcomed 86 listed companies raising over US$17.8 billion since 2018, to list in Hong Kong even before generating revenue. This regulatory approach provides market access opportunities for companies still focused on research and clinical development.
Hong Kong-listed biotech stocks are showing signs of increasing maturity. Within the Hang Seng Biotech Index (HSBIO), which tracks 30 leading, predominantly China‑based biotech firms, companies that have reached commercialisation accounted for over 95.8% of the index by weight as of end-May 2026, while around 4.2% remained pre-revenue. Furthermore, the average time for companies to remove their pre-revenue "B" designation is around 2.6 years, underscoring the accelerating commercialisation cycle of China’s biotech companies.
At the same time, earlier-stage biotechnology investing can be more volatile. Share prices may move sharply on clinical trial updates, regulatory milestones, licensing announcements, or fundraising activity, not only on earnings. For investors seeking exposure while mitigating single‑stock risk, broad‑based ETFs such as those tracking HSBIO offer a more balanced approach. Today, Hong Kong offers a deepening liquidity ecosystem around this sector, including cash equities, ETFs, and index futures, providing various tools for market participation.
China's biotechnology sector represents an area of significant market attention within Hong Kong's capital markets. With a robust market structure anchored by the Chapter 18A framework and a growing ecosystem of index-linked products, Hong Kong provides investors with diverse pathways to access this maturing sector. While understanding these drivers contributes to broader financial literacy, investors considering portfolio allocation to biotechnology should carefully weigh these opportunities against the inherent volatility and their own risk tolerance.
Note:
1. Source: WHO
2. Source: SCMP
3. Source: Biotechnology Blueprint
Disclaimer:
1. This educational overview is not a substitute for professional financial advice. Market participants should consult with qualified financial advisors and conduct thorough due diligence before making any investment decisions.
2. Investment involves risks. The price of investment products may fluctuate or even become worthless. Past performance is not an indicator of future performance. Losses may be incurred rather than making a profit as a result of investment. The information in this platform is for reference only and does not constitute and should not be regarded as any recommendation, offer or solicitation to purchase or sell any investment products. You should carefully and independently consider whether the investment products are suitable for you in light of your investment experience, objectives, financial position and risk profile. Independent professional advice should be obtained if necessary. Please read the relevant terms and conditions together with the offering document and risk disclosure statements of the investment product before making any investment decisions. The information in this platform has not been reviewed by SFC or any regulatory authority in Hong Kong. ZA Bank is acting as your agent to handle the transaction. The investment product is provided by a third party but not ZA Bank. In respect of an eligible dispute (as defined in the terms of reference for the Financial Dispute Resolution Centre in relation to the Financial Dispute Resolution Scheme) out of the selling process or processing of the related transaction, ZA Bank will enter a Financial Dispute Resolution Scheme process with you. However, any disputes over the contractual terms of the product should be resolved directly between you and the third-party product issuer. The platform is not intended for distribution or use by any person in any jurisdiction, country or region where the distribution or use of this material is restricted and would not be permitted by law or regulation. If you are outside of Hong Kong, we may not be authorised to offer or provide you with the products and services available in the country or region where you are located or resident.